Market Expansion:
Multiple drugmakers have recently shifted contract‑pharmacy data/designation workflows to Truzo (e.g., Organon effective May 1, 2026; Gilead July 7, 2026; Alkermes December 1, 2025), signaling expanding platform uptake. Industry commentary in early 2026 also framed Kalderos/Truzo as a viable path amid 340B uncertainty, reinforcing active market presence.
Investor Backing & Capital Strength:
A new funding round on January 3, 2025 and cumulative capital raised across multiple rounds indicate solid financial support to scale go‑to‑market and product. The June 17, 2026 acquisition by Model N further demonstrates external conviction in Kalderos’ strategic value.
Strategic Partnerships:
Model N’s acquisition integrates Kalderos’ 340B and GTN capabilities into a broader life‑sciences revenue platform, providing access to established distribution channels. Notices and industry records highlight collaboration with major manufacturers, reflecting deepening commercial ties.
